By Dominic Chopping
Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.
Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added.
In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.
Novo Nordisk expects to launch Ozempic 2.0 milligram in the U.S. in the second quarter of 2022.
Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.
Write to Dominic Chopping at firstname.lastname@example.org